Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PAVmed (PAVM) Research & Development (2021 - 2025)

PAVmed has reported Research & Development over the past 5 years, most recently at $1.8 million for Q4 2025.

  • Quarterly results put Research & Development at $1.8 million for Q4 2025, up 126.52% from a year ago — trailing twelve months through Dec 2025 was $4.5 million (down 43.72% YoY), and the annual figure for FY2025 was $4.5 million, down 24.28%.
  • Research & Development for Q4 2025 was $1.8 million at PAVmed, up from $1.1 million in the prior quarter.
  • Over the last five years, Research & Development for PAVM hit a ceiling of $7.0 million in Q4 2021 and a floor of $787000.0 in Q1 2025.
  • Median Research & Development over the past 5 years was $3.5 million (2023), compared with a mean of $3.6 million.
  • Biggest five-year swings in Research & Development: crashed 77.55% in 2024 and later surged 126.52% in 2025.
  • PAVmed's Research & Development stood at $7.0 million in 2021, then fell by 4.23% to $6.7 million in 2022, then crashed by 46.13% to $3.6 million in 2023, then plummeted by 77.55% to $807000.0 in 2024, then surged by 126.52% to $1.8 million in 2025.
  • The last three reported values for Research & Development were $1.8 million (Q4 2025), $1.1 million (Q3 2025), and $790000.0 (Q2 2025) per Business Quant data.